TLDR
- BioMarin and Ascendis Pharma reached a global settlement resolving all patent disputes over Ascendis’s drug Yuviwel.
- Ascendis will pay BioMarin a 20% royalty on U.S. net sales and 18% on sales in the EU, Brazil, and South Korea.
- Royalty payments are retroactive to Yuviwel’s first commercial sale and run until May 2030.
- The deal covers all current and potential indications for Yuviwel, including achondroplasia and hypochondroplasia.
- BioMarin will drop its Section 337 investigation at the ITC and dismiss related litigation across multiple countries.
BioMarin Pharmaceutical (BMRN) reached a global patent settlement with Ascendis Pharma on August 30, 2026, ending a legal battle over CNP technology used in Ascendis’s drug Yuviwel. BMRN stock was down 0.96% around the time of the announcement.
BioMarin Pharmaceutical Inc., BMRN
The two companies had been locked in disputes across multiple jurisdictions, including proceedings before the U.S. International Trade Commission. The settlement wraps up all of that in one agreement.
Under the deal, Ascendis will pay BioMarin a royalty of 20% of Yuviwel’s net U.S. sales, retroactive to the drug’s first commercial sale. In the EU, Brazil, and South Korea, the royalty rate is 18% of net sales. All payments run until May 2030.
The license covers Yuviwel across all current and potential uses, including achondroplasia, hypochondroplasia, and combination therapies. That’s a broad scope that protects BioMarin’s IP well beyond the primary indication.
What BioMarin Gives Up and Gets
In exchange, BioMarin will dismiss its Section 337 investigation at the ITC. Litigation pending in Brazil, Denmark, Germany, South Korea, and the Northern District of California will also be resolved.
Ascendis also agreed not to challenge BioMarin’s patent rights and accepted a mutual regulatory non-interference clause. That’s a meaningful concession from Ascendis.
The settlement validates BioMarin’s CNP platform, which includes its own drug VOXZOGO (vosoritide) for children with achondroplasia. BioMarin spent years developing the underlying science, and the royalty stream is a direct return on that investment.
BioMarin’s Position in Rare Disease
BioMarin CEO Alexander Hardy called the outcome a sign that long-term investment in rare disease innovation is worth it. The company has nine commercial therapies and has developed six first-in-disease medicines.
The most recent analyst rating on BMRN is a Buy with a price target of $88.00. The stock has a market cap of around $12.52 billion.
BioMarin’s technical sentiment is flagged as a Buy, with the price sitting above major moving averages and a positive MACD signal. That said, analysts have flagged a recent drop in profitability and return on equity, along with a high P/E valuation.
The company raised its 2026 revenue guidance on its most recent earnings call, which added some positive momentum heading into the back half of the year.
The settlement adds a new royalty revenue line tied to Yuviwel sales across four major markets, which will feed into BioMarin’s financials through May 2030.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
